A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE

This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.